Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 1, 2008, Pages 20-24

  Fossmark, Reidar ^a,b   Jianu, Constantin S ^a   Martinsen, Tom C ^a,b   Qvigstad, Gunnar ^a,b   Syversen, Unni ^a,b   Waldum, Helge L ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Chromogranin A; Fundic gland polyps; Gastrin; Helicobacter pylori; Proton pump inhibitors

Indexed keywords

CHROMOGRANIN A; ESOMEPRAZOLE; GASTRIN; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CHROMAFFIN CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; LONG TERM CARE; MEAL; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH FUNDUS; STOMACH PH; STOMACH POLYP;

ARYL HYDROCARBON HYDROXYLASES; CHROMOGRANIN A; GASTRIC ACIDITY DETERMINATION; GASTRIC FUNDUS; GASTRINS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYPS; PROTON PUMP INHIBITORS; STOMACH DISEASES;

EID: 37549064376     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701561959     Document Type: Article

References (29)

1. Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust 1992;157:287-8.
2. Graham JR. Omeprazole and gastric polyposis in humans. Gastroenterology 1993;104:1584.
3. Jalving M, Koornstra JJ, Wesseling J, Boezen HM, Jong S DE, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006;24:1341-8.
4. Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998;110:615-21.
5. Torbenson M, Lee JH, Cruz-Correa M, Ravich W, Rastgar K, Abraham SC, et al. Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis. Mod Pathol 2002;15:718-23.
6. Wu TT, Kornacki S, Rashid A, Yardley JH, Hamilton SR. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol 1998;22:293-8.
7. Wallace MH, Phillips RK. Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 1998;85:742-50.
8. Zwick A, Munir M, Ryan CK, Gian J, Burt RW, Leppert M, et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997;113:659-63.
9. Flick AL. Gastric fundal polyps with cellular atypia in a patient using esomeprazole (Nexium). Dig Dis Sci 2005;50:2100-2.
10. Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, Sundell G, et al. Plasma gastrin and gastric enterochromaf-finlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986;90:391-9.
11. Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986;35 Suppl 1:42-55.
12. Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-7.
13. Food and Drug Administration. FDA background. Omeprazole magensium (Prilosec 1 TM) Astra Zeneca with Proctor and Gamble. For the Joint Meeting of the Nonprescription Drugs Advisory Committee and the Gastrointestinal Drugs Advisory Committee on October 20, 2000.
14. Qvigstad G, Qvigstad T, Westre B, Sandvik AK, Brenna E, Waldum HL. Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS 2002;110:132-9.
15. Waldum HL, Aase S, Kvetnoi I, Brenna E, Sandvik AK, Syversen U, et al. Neuroendocrine differentiation in human gastric carcinoma. Cancer 1998;83:435-44.
16. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996;39:649-53.
17. el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997;92:1858-60.
18. Waldum HL, Sandvik AK, Brenna E, Petersen H. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut 1991;32:698-701.
19. Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005;21:149-54.
20. Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using Iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 1985;20:569-76.
21. Syversen U, Jacobsen MB, O'Connor DT, Ronning K, Waldum HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994;26:201-6.
22. Waldum HL, Brenna E, Sandvik AK, Petersen H. Trophic effect of histamine on the stomach. Scand J Gastroenterol 1991;Suppl 180:137-42.
23. Watson SA, Wilkinson LJ, Robertson JF, Hardcastle JD. Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine. Gut 1993;34:1091-6.
24. Fukui H, Kinoshita Y, Maekawa T, Okada A, Waki S, Hassan S, et al. Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology 1998;115:1483-93.
25. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23-32.
26. 2 receptor. Gastroenterology 2003;124:615-25.
27. Smith JT, Pounder RE, Nwokolo CU, Lanzon-Miller S, Evans DG, Graham DY, et al. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut 1990;31:522-5.
28. Håkanson R, Ding XQ, Norlen P, Chen D. Circulating pancreastatin is a marker for the enterochromaffin-like cells of the rat stomach. Gastroenterology 1995;108:1445-52.
29. Sanduleanu S, De Bruine A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001;31:802-11.